Athersys (ATHX) Soars 16% Ahead of Earnings
Athersys (ATHX) Soared 16.4% today ahead of their earnings date coming up on Friday, May 6th.
In addition, the CEO Daniel Camardo recently bought 132,800 shares of the Company’s stock on March 17th at an average price of $0.77. Institutional investors have also made recent acquisitions, which may be a positive sign for the Company in the future.
Athersys is a biotech company that focuses on research and development in the field of regenerative medicine. ATHX is housed in the PRISM Vaccines & Cell Therapy Index, which was the best performing PRISM index of the day, finishing up 4.8%.